Melena Bellin, MD
Pediatric Endocrinology · Minneapolis, MNNPI 1124219043
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,474 of the $56,256 with a category attached, or 84.4%. Vertex accounts for 85.3% of it on its own, with 5 other manufacturers making up the rest.
Across 80 payments — averaging $703.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$48K
- Novo Nordisk AS$8K
- Medtronic$175
- Insulet Corporation$162
- Boston Scientific$77
- Sanofi-aventis U.S. LLC$73
Across 8 payments — averaging $11,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$90K
- Dexcom, Inc.$3K
- Insulet Corporation$2K
What the payments were for
- Consulting fees$47,47484%
- Travel & lodging$7,53713%
- Food & beverage$1,2452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 67 | $47,966 |
| Novo Nordisk AS | 6 | $7,802 |
| Medtronic(2 entities) | 3 | $175 |
| Insulet Corporation | 2 | $162 |
| Boston Scientific | 1 | $77 |
| Sanofi-aventis U.S. LLC | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$148
How this compares
$56,256 in reported general payments places this provider in the 80th percentile of 25 pediatric endocrinology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 38 | $124,132 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $22,793 |
| Mycophenolic AcidMycophenolate Sodium | 25 | $7,700 |
| Tacrolimus | 83 | $5,200 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,499 |
| Mycophenolate Mofetil | 14 | $1,468 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,238 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $100 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Minneapolis
- Bradley MillerMinneapolis$465K
- Antoinette MoranMinneapolis$63K
- Brandon NathanMinneapolis$11K
- Megan BensignorMinneapolis$886
- Silpa NadellaMinneapolis$371
- Sarah MurphyMinneapolis$208
- Matthew WiseMinneapolis$148
- Eric BombergMinneapolis$60
- Elwaseila HamdounMinneapolis$18
- Anna PetrykMinneapolis$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.